CLOs on the Move

AxelaCare Health Solutions

www.axelacare.com

 
AxelaCare Health Solutions is a Lenexa, KS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

MEM SLOAN KETTERING CANCER C

MEM SLOAN KETTERING CANCER C is a New York, NY-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

PanCare

PanCare Health Offers Health Care Services In Multiple Locations, Including Freeport And Bonifay, FL For Urgent Care, Affordable Therapy, And More. Call Today!

MassMEDIC

The Heart of Healthtech Beats Here. We proudly serve as the voice of the #healthtech industry in New England, representing companies changing the world.

Savara Pharmaceuticals

Savara Inc. is an orphan lung disease company. Savara`s pipeline comprises: Molgradex, an inhaled granulocyte-macrophage colony-stimulating factor, or GM-CSF, in Phase 3 development for PAP, and in Phase 2a development for NTM lung infection; and AeroVanc, a Phase 3 stage inhaled vancomycin for treatment of MRSA infection in cystic fibrosis. Savara`s strategy involves expanding its pipeline of potentially best-in-class products through indication expansion, strategic development partnerships and product acquisitions, with the goal of becoming a leading company in its field. Savara`s management team has significant experience in orphan drug development and pulmonary medicine, in identifying unmet needs, developing and acquiring new product candidates, and effectively advancing them to approvals and commercialization.

Phathom Pharmaceuticals

Phathom Pharmaceuticals, launched in 2019 by Frazier Healthcare Partners and Takeda Pharmaceuticals, is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal (GI) diseases and disorders. The company is advancing the investigational agent vonoprazan, a novel potassium-competitive acid blocker (P-CAB). Vonoprazan has the potential to address multiple unmet needs among patients with gastroesophageal reflux disease (GERD) and other acid-related disorders.